Monthly Archives: November 2016

Home/2016/November

Liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic cancer

Madappa N. Kundranda Genomic change index (GCI) and liquid biopsies in predicting and monitoring response to therapy in advanced pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 33, 2015 (suppl 3; abstr 309).

Advanced PDAC is a lethal disease with dismal 5 year survival. The current modalities for monitoring therapy response using serum (CA) 19-9 levels have poor specificity and radiological responses have long lag times. Tests for rapid and accurate clinical assessment are needed for early decision making.

By |2020-11-30T10:11:48+00:00November 2, 2016|Other publications|0 Comments
Read More

Prognostic value of cell-free DNA in patients with oropharyngeal cancers

Julia Beck, Margret Rave-Fraenk, et al. Prognostic value of cell-free DNA in patients with oropharyngeal cancers.J Clin Oncol 34, 2016 (suppl; abstr e17511).

Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.

By |2020-11-30T10:11:48+00:00November 2, 2016|Other publications|0 Comments
Read More

Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.

Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.J Clin Oncol 33, 2015 (suppl; abstr e22020) .

Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response.

By |2020-11-30T10:11:49+00:00November 2, 2016|Other publications|0 Comments
Read More

Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort.

Ekkehard Schütz, Howard B. Urnovitz, et al. Quantifying copy number variations in cell-free DNA for potential clinical utility from a large prostate cancer cohort J Clin Oncol 31, 2013 (suppl; abstr 5072).

Prostate cancer (PrCa) is the most frequent non-dermatological malignancy in the male population. Genomic instability resulting in copy number variation (CNV) is a hallmark of malignant transformation.

By |2020-11-30T10:11:49+00:00November 2, 2016|Other publications|0 Comments
Read More
Go to Top